KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Capital Leases (2016 - 2018)

Historic Capital Leases for Gsk (GSK) over the last 3 years, with Q4 2018 value amounting to $56.6 million.

  • Gsk's Capital Leases fell 82.65% to $56.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $56.6 million, marking a year-over-year decrease of 82.65%. This contributed to the annual value of $58.8 million for FY2018, which is 608.46% up from last year.
  • Gsk's Capital Leases amounted to $56.6 million in Q4 2018, which was down 82.65% from $57.1 million recorded in Q4 2017.
  • In the past 5 years, Gsk's Capital Leases ranged from a high of $57.1 million in Q4 2017 and a low of $51.0 million during Q4 2016
  • For the 3-year period, Gsk's Capital Leases averaged around $54.9 million, with its median value being $56.6 million (2018).
  • In the last 5 years, Gsk's Capital Leases skyrocketed by 1200.16% in 2017 and then plummeted by 82.65% in 2018.
  • Over the past 3 years, Gsk's Capital Leases (Quarter) stood at $51.0 million in 2016, then grew by 12.0% to $57.1 million in 2017, then fell by 0.83% to $56.6 million in 2018.
  • Its Capital Leases stands at $56.6 million for Q4 2018, versus $57.1 million for Q4 2017 and $51.0 million for Q4 2016.